How Rybelsus and Compounded Tirzepatide work — mechanism comparison
Rybelsus (semaglutide) and Compounded Tirzepatide (tirzepatide (compounded)) belong to overlapping but distinct drug classes. Both work via the incretin (gut-hormone) pathway, but they have different molecular targets:
- Rybelsus (semaglutide) — GLP-1 receptor agonist
- Compounded Tirzepatide (tirzepatide (compounded)) — GLP-1 receptor agonist
This mechanistic difference matters because it determines: efficacy (how much weight loss / blood-sugar control you can expect), side-effect profile, dosing schedule, and which patients may benefit most. Read more in our Rybelsus mechanism guide and Compounded Tirzepatide mechanism guide.
Efficacy head-to-head
In their respective pivotal trials, mean body-weight reduction reached:
- Rybelsus: 4% at 26 weeks (trial: PIONEER)
- Compounded Tirzepatide: no weight-loss trial of its own
Side-by-side radar: Rybelsus vs Compounded Tirzepatide
Editorial scoring across 5 dimensions, overlaid. Higher area = better overall fit.
| Axis | Rybelsus | Compounded Tirzepatide |
|---|---|---|
| Efficacy | 6 | 10 |
| Convenience | 8 | 9 |
| Affordability | 6 | 5 |
| Tolerance | 5 | 6 |
| Evidence | 10 | 6 |
Higher score = better on that axis. Editorial scoring; not a substitute for prescriber judgment.
Side effects compared
Both drugs share the GLP-1 class side-effect profile — primarily gastrointestinal (nausea, diarrhea, constipation, vomiting) in early treatment, fading as the body adapts. Both carry the FDA boxed warning for thyroid C-cell tumors and contraindications for personal/family history of medullary thyroid carcinoma.
Side-effect rate comparator
Trial-derived adverse-event rates with placebo delta. Sourced from FDA-approved labels for each drug. Most sources omit placebo rates entirely.
| Adverse event | Rybelsus | Compounded Tirzepatide |
|---|---|---|
| Nausea | 20%(placebo 6%) +14.0 pp vs placebo | 28%(placebo 8%) +20.0 pp vs placebo |
| Diarrhea | 10%(placebo 4%) +6.0 pp vs placebo | 23%(placebo 8%) +15.0 pp vs placebo |
| Vomiting | 8%(placebo 3%) +5.0 pp vs placebo | 13%(placebo 2%) +11.0 pp vs placebo |
| Abdominal pain | 11%(placebo 4%) +7.0 pp vs placebo | 10%(placebo 5%) +5.0 pp vs placebo |
| Constipation | 5%(placebo 2%) +3.0 pp vs placebo | 11%(placebo 5%) +6.0 pp vs placebo |
| Dyspepsia | — | 10%(placebo 4%) +6.0 pp vs placebo |
| Decreased appetite | 9%(placebo 1%) +8.0 pp vs placebo | — |
| Injection-site reactions | — | 8%(placebo 2%) +6.0 pp vs placebo |
| Fatigue | — | 7%(placebo 3%) +4.0 pp vs placebo |
Patients who tolerate one GLP-1 well often (but not always) tolerate another. Switching between class members typically requires re-titration regardless of prior tolerability. See full side-effect breakdowns for Rybelsus and Compounded Tirzepatide.
Dosing schedule comparison
Both medications use step-up titration to minimize side effects, but the schedule details differ:
Rybelsus
- Days 1–30: 3 mg/day
- Days 31–60: 7 mg/day
- Day 61+: 7 mg or 14 mg/day
Compounded Tirzepatide
- Week 1–4: 2.5 mg
- Week 5–8: 5 mg
- Week 9+: 7.5–15 mg
- Maintenance: Up to 15 mg
See full titration guides for Rybelsus dosing and Compounded Tirzepatide dosing.
Cost comparison
Cost differences between Rybelsus and Compounded Tirzepatide depend on insurance coverage, manufacturer savings programs, and partner-network pricing — not just retail price.
- Average retail price (Rybelsus): $968/month
- Average retail price (Compounded Tirzepatide): $299/month
- Rybelsus savings card: as low as $25/month for eligible commercial-insured
- Compounded Tirzepatide savings card: no standing savings card
For most patients, the actual out-of-pocket cost is driven by: (1) what your insurance formulary tier places Rybelsus vs Compounded Tirzepatide, (2) whether you qualify for manufacturer savings cards (commercial insurance only), and (3) telehealth partner network availability. Full cost breakdowns: Rybelsus cost guide · Compounded Tirzepatide cost guide.
Which one to choose — decision factors
There's no single «better» drug — the right choice depends on individual circumstances. The key decision factors:
Choose Rybelsus if…
- Your insurance covers it but not Compounded Tirzepatide
- Your prescriber has more experience with it
- You prefer drugs with longer post-market track record
- You're commercially insured and want maximum savings-card benefit
Choose Compounded Tirzepatide if…
- Your insurance covers it but not Rybelsus
- Your prescriber has more experience with it
Switching from Rybelsus to Compounded Tirzepatide (or vice versa)
Switching between Rybelsus and Compounded Tirzepatide (different active ingredients) typically requires restarting titration from the lowest doseof the new drug. Different molecules have different potencies — your tolerated dose of one doesn't map directly to the other. Plan for:
- Return of titration-period side effects (nausea, GI) for 2-4 weeks on restart
- Possibly temporary weight regain during the transition
- Fresh insurance prior-authorization (different drug = new PA)
- 2-4 weeks for the new drug to reach steady-state plasma levels
FAQ — Rybelsus vs Compounded Tirzepatide
Are Rybelsus and Compounded Tirzepatide the same drug?
No — they contain different active ingredients (semaglutide and tirzepatide (compounded)). They belong to similar drug classes (GLP-1 family) but work via slightly different molecular targets.
Which is more effective for weight loss, Rybelsus or Compounded Tirzepatide?
Rybelsus produced about 4% average weight loss in PIONEER. Compounded Tirzepatide has no weight-loss trial of its own to set against it, so the two cannot be ranked on weight loss.
Can I take Rybelsus and Compounded Tirzepatide together?
No. Combining two GLP-1 receptor agonists provides no added benefit and dramatically increases side-effect risk. Standard practice is to switch between them, not combine them.
Which has fewer side effects, Rybelsus or Compounded Tirzepatide?
Both mostly cause stomach side effects such as nausea and diarrhea, which tend to ease with time. We do not hold comparable placebo-controlled rates for both, so we do not rank them on side effects.
Will my insurance cover Rybelsus but not Compounded Tirzepatide?
Often the coverage differs. Insurance formularies are negotiated separately per drug — Rybelsus may be on Tier 2 of your plan while Compounded Tirzepatide is Tier 4 or excluded. Check your formulary before assuming both are equally accessible.
Editorial comparison based on FDA prescribing information and published clinical data. Not a substitute for prescriber consultation. Full medical disclaimer.